Doxorubicin as an antioxidant: Maintenance of myocardial levels of lycopene under doxorubicin treatment

Free Radical Biology and Medicine

Volumn 43, Issue 5, 2007, Pages 740-751

  Ferreira, Ana Lucia Anjos ^a   Yeum, Kyung Jin ^b   Matsubara, Luiz Shiguero ^a   Matsubara, Beatriz Bojikian ^a   Correa, Camila R ^a   Pereira, Elenize Jamas ^a   Russell, Robert Mitchell ^b   Krinsky, Norman I ^b,c   Tang, Guangwen ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b TUFTS UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant capacity; Doxorubicin; Enzymatic cleavage; Heart; Lycopene; Oxidative cleavage; Rat

Indexed keywords

DOXORUBICIN; IDARUBICIN; LIPOXYGENASE; LYCOPENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HEART MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE MUCOSA; MALE; NONHUMAN; OXIDATION KINETICS; PRIORITY JOURNAL; RAT; TISSUE LEVEL;

ANIMALS; ANTIOXIDANTS; CAROTENOIDS; CATALYSIS; CHROMATOGRAPHY, LIQUID; DOXORUBICIN; HEART; KINETICS; LYCOPERSICON ESCULENTUM; MALE; MASS SPECTROMETRY; MOLECULAR STRUCTURE; MYOCARDIUM; OLEANDOMYCIN; OXIDATION-REDUCTION; RATS; RATS, WISTAR; TETRACYCLINE;

RATTUS; RATTUS NORVEGICUS;

EID: 34547106844     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.05.002     Document Type: Article

References (68)

1. Buja L.M., Ferrans V.J., Mayer R.J., Roberts W.C., and Henderson E.S. Cardiac ultraestructural changes induced by daunorubicin therapy. Cancer 32 (1973) 771-788
2. Li T., Danelisen I., and Singal P.K. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol. Cell. Biochem. 232 (2002) 19-26
3. Lee V., Randhawa A.K., and Singal P.K. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am. J. Physiol. 261 (1991)
4. Wahab M.H.A., Akoul E.E.M.S., and Abdelaziz A.H. Modulatory effects of melatonin and vitamin-E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma bearing mice. Tumori 86 (2000) 157-162
5. Antunes L.M., and Takahashi C.S. Effects of high doses of vitamins C and E against doxorubicin-induced chromosomal damage in Wistar rat bone marrow cells. Mutat. Res. 419 (1998) 137-143
6. Vile G.F., and Winterbourn C.C. Inhibition of adriamycin-promoted microsomal lipid peroxidation by beta-carotene, alpha-tocopherol and retinol at high and low oxygen partial pressures. FEBS Lett. 238 (1988) 353-356
7. Teicher B.A., Schwartz J.L., Holden S.A., Ara G., and Northey D. In vivo modulation of several anticancer agents by beta-carotene. Cancer Chemother. Pharmacol. 34 (1994) 235-241
8. van Acker F.A., Hulshof J.W., Haenen G.R., Menge W.M., van der Vijgh W.J., and Bast A. New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Radic. Biol. Med. 31 (2001) 31-37
9. Danelisen I., Palace V., Lou H., and Singal P.K. Maintenance of myocardial levels of vitamin A in heart failure due to adriamycin. J. Mol. Cell. Cardiol. 34 (2002) 789-795
10. Arab L., and Steck S. Lycopene and cardiovascular disease. Am. J. Clin. Nutr. 71 (2000) 1691S-1695S
11. Stahl W., and Sies H. Physical quenching of singlet oxygen and cis-trans isomerization of carotenoids. Ann. N. Y. Acad. Sci. 691 (1993) 10-19
12. Di Mascio P., Kaiser S., and Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch. Biochem. Biophys. 274 (1989) 532-538
13. Stahl W., and Sies H. Antioxidant activity of carotenoids. Mol. Aspects Med. 24 (2003) 345-351
14. Karimi G., Ramezani M., and Abdi A. Protective effects of lycopene and tomato extract against doxorubicin-induced cardiotoxicity. Phytother. Res. 19 (2005) 912-914
15. Yilmaz S., Atessahin A., Sahna E., Karahan I., and Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 218 (2006) 164-171
16. Yeum K.-J., Ferreira A.L.A., Smith D., Krinsky N.I., and Russell R.M. The effect of a-tocopherol on the oxidative cleavage of β-carotene. Free Radic. Biol. Med. 29 (2000) 105-114
17. Tang G.W., Wang X.D., Russell R.M., and Krinsky N.I. Characterization of beta-apo-13-carotenone and beta-apo-14′-carotenal as enzymatic products of the excentric cleavage of beta-carotene. Biochemistry 30 41 (1991) 9829-9834
18. Wang X.-D., Krinsky N.I., Tang G., and Russell R.M. Retinoic acid can be produced from excentric cleavage of β-carotene in human intestinal mucosa. Arch. Biochem. Biophys. 293 (1992) 293-304
19. Krinsky N.I., Wang X.-D., Tang G., and Russell R.M. Conversion of carotenoids to retinoids (1993), Dekker, New York
20. Yeum K.-J., Lee-Kim Y.C., Yoon S., Lee K.Y., Park I.S., Lee K.S., Kim B.S., Tang G., Russell R.M., and Krinsk N.I. Similar metabolites formed from β-carotene by either human gastric mucosal homogenates, lipoxygenase or linoleic acid hydroperoxide. Arch. Biochem. Biophys. 321 (1995) 167-174
21. Ferreira A.L.A., Yeum K.-J., Russell R.M., Tang G., and Krinsky N.I. Enzymatic oxidative metabolites of lycopene. J. Nutr. Biochem. 14 (2003) 531-540
22. Paiva S.A., Novo R., Matsubara B.B., Matsubara L.S., Azevedo P.S., Minicucci M.F., Campana A.O., and Zornoff L.A. Beta-carotene attenuates the paradoxical effect of tobacco smoke on the mortality of rats after experimental myocardial infarction. J. Nutr. 135 (2005) 2109-2113
23. Abdel-aleem S., el-Merzabani M.M., Sayed-Ahmed M., Taylor D.A., and Lowe J.E. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J. Mol. Cell. Cardiol. 29 (1997) 789-797
24. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., and Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci. 65 (1999) 1265-1274
25. Nagao A., During A., Hoshino C., Terao J., and Olson J.A. Stoichiometric conversion of all trans-b-carotene to retinal by pig intestinal extract. Arch. Biochem. Biophys. 328 (1996) 57-63
26. During A., Nagao A., Hoshino C., and Terao J. Assay of β-carotene 15,159-dioxygenase activity by reverse-phase high-pressure liquid chromatography. Anal. Biochem. 241 (1996) 199-205
27. Ferreira A.L.A., Yeum K.-J., Liu C., Smith D., Krinsky N.I., Wang X.-D., and Russell R.M. Tissue distribution of lycopene in ferrets and rats after lycopene supplementation. J. Nutr. 130 (2000) 1256-1260
28. Beretta G., Aldini G., Facino R.M., Russell R.M., Krinsky N.I., and Yeum K.J. Total antioxidant performance: a validated fluorescence assay for the measurement of plasma oxidizability. Anal. Biochem. 354 (2006) 290-298
29. Aldini G., Yeum K., Russell R.M., and Krinsky N.I. A method to measure the oxidizability of both the aqueous and lipid compartments of plasma. Free Radic. Biol. Med. 31 (2001) 1043-1050
30. Wang X.D., Tang G.W., Fox J.G., Krinsky N.I., and Russell R.M. Enzymatic conversion of beta-carotene into beta-apo-carotenals and retinoids by human, monkey, ferret, and rat tissues. Arch. Biochem. Biophys. 285 (1991) 8-16
31. Kim S.J., Nara E., Kobayashi H., Terao J., and Naga A. Formation of cleavage products by autoxidation of lycopene. Lipids 36 (2001) 191-199
32. Manchand P.S., Ruegg R., Schwieter U., Siddons P.T., and Weedon B.C.L. Carotenoids and related compounds. XI. Syntheses of delta-carotene and epson-carotene. J. Chem. Soc. 46 (1965) 2019-2026
33. Khachik F., Steck A., Niggli U.A., and Pfander H. Partial synthesis and structural elucidation of the oxidative metabolites of lycopene identified in tomato paste, tomato juice, and human serum. J. Agric. Food Chem. 46 (1998) 4874-4884
34. Paetau I., Khachik F., Brown E.D., Beecher G.R., Kramer T.R., Chittams J., and Clevidence B.A. Chronic ingestion of lycopene-rich tomato juice or lycopene supplements significantly increases plasma concentrations of lycopene and related tomato carotenoids in humans. Am. J. Clin. Nutr. 68 (1998) 1187-1195
35. Lefrak E.A., Pitha J., Rosenheim S., and Gottieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32 (1973) 302-314
36. 111In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Morphological and hemodynamic findings. Circulation 86 (1992) 1965-1972
37. Deepa P.R., and Varalakshmi P. The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity. Eur. J. Pharmacol. 478 (2003) 199-205
38. Chen D., Zhang X.Y., and Shi Y. Identification and functional characterization of hCLS1, a human cardiolipin synthase localized in mitochondria. Biochem. J. 398 (2006) 169-176
39. Goormaghtigh E., and Ruysschaert J.M. Anthracycline glycoside-/membrane interactions. Biochim. Biophys. Acta 779 (1984) 271-288
40. Davies K.J.A., and Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261 (1986) 3060-3067
41. Nohl H. Identification of the site of adriamycin-activation in the heart cell. Biochem. Pharmacol. 37 (1988) 2633-2637
42. Nohl H. Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. Eur. J. Biochem. 169 (1987) 585-591
43. Schönheit K., and Nohl H. Oxidation of cytosolic NADH via complex I of heart mitochondria. Arch. Biochem. Biophys. 327 (1996) 319-323
44. Gille L., and Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic. Biol. Med. 23 (1997) 775-782
45. Singal P.K., Siveski-Iliskovic N., Hill M., Thomas T.P., and Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 27 (1995) 1055-1063
46. Kotamraju S., Konorev E.A., Joseph J., and Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. 275 (2000) 33585-33592
47. Van Vleet J.F., Ferrans V.J., and Weirich W.E. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol. 99 (1980) 13-42
48. Breed J.G., Zimmerman A.N., Dormans J.A., and Pinedo H.M. Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res. 40 (1980) 2033-2038
49. Legha S.S., Wang Y.M., Mackay B., Ewer M., Hortobagyi G.N., Benjamin R.S., and Ali M.K. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann. N. Y. Acad. Sci. 393 (1982) 411-418
50. Myers C., Bonow R., Palmeri S., Jenkins J., Corden B., Locker G., Doroshow J., and Epstein S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10 (1983) 53-55
51. Olson R.D., Mushlin P.S., Brenner D.E., Fleischer S., Cusack B.J., Chang B.K., and Boucek R.J. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. USA 85 (1988) 3585-3589
52. Minotti G., Cavaliere A.F., Mordente A., Rossi M., Schiavello R., Zamparelli R., and Possati G. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines: novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J. Clin. Invest. 95 (1995) 1595-1605
53. Dodd D.A., Atkinson J.B., Olson R.D., Buck S., Cusack B.J., Fleischer S., and Boucek R.J.J. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J. Clin. Invest. 91 (1993) 1697-1705
54. Zhou S., Starkov A., Froberg M.K., Leino R.L., and Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61 (2001) 771-777
55. Siveski-Iliskovic N., and Singal P.K. Lipid lowering: an important factor in preventing adriamycin- induced heart failure. Am. J. Pathol. 150 (1997) 727-734
56. Hong Y.M., Kim H.S., and Yoon H.-R. Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine. Pediatr. Res. 51 (2002) 249-255
57. Kitagawa K., Takeda K., Saito K., Okamoto S., Makino K., Maeda H., and Ichihara T. Differences in fatty acid metabolic disorder between ischemic myocardium and doxorubicin-induced myocardial damage: assessment using BMIPP dynamic SPECT with analysis by the Rutland method. J. Nucl. Med. 43 (2002) 1286-1294
58. Lü H.Z., Geng B.Q., Zhu Y.L., and Yong D.G. Effects of beta-carotene on doxorubicin-induced cardiotoxicity in rats. Acta Pharmacol. Sin. 17 (1996) 317-320
59. Ciaccio M., Valenza M., Tesoriere L., Bongiorno A., Albiero R., and Livrea M.A. Vitamin-A inhibits doxorubicin-induced membrane lipid-peroxidation in rat-tissues in vivo. Arch. Biochem. Biophys. 302 (1993) 103-108
60. Yin X., Wu H., Chen Y., and Kang Y.J. Induction of antioxidants by adriamycin in mouse heart. Biochem. Pharmacol. 56 (1998) 87-93
61. Dziegiel P., Murawska-Cialowicz E., Jethon Z., Januszewska L., Podhorska-Okolow M., Surowiak P., Zawadzki M., Rabczynski J., and Zabel M. Melatonin stimulates the activity of protective antioxidative enzymes in myocardial cells of rats in the course of doxorubicin intoxication. J. Pineal Res. 35 (2003) 183-187
62. Minotti G., Mancuso C., Frustaci A., Mordente A., Santini S.A., Calafiore A.M., Liberi G., and Gentiloni N. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. J. Clin. Invest. 98 (1996) 650-661
63. Erhola M., Kellokumpu-Lehtinen P., Metsa-Ketela T., Alanko K., and Nieminen M.M. Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients. Free Radic. Biol. Med. 21 (1996) 383-390
64. Faure H., Coudray C., Mousseau M., Ducros V., Douki T., Bianchini F., Cadet J., and Favier A. 5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycin-treated patients. Free Radic. Biol. Med. 20 (1996) 979-983
65. Iwase H., Sakurada K., Takatori T., Nagao M., Niijima H., Matsuda Y., and Kobayashi M. Calcium ions potentiate lipoxygenase activity of cytochrome c at the physiological pH. Biochem. Biophys. Res. Commun. 243 (1998) 485-491
66. Hammarberg T., Provost P., Persson B., and Radmark O. The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J. Biol. Chem. 275 (2000) 38787-38793
67. Ferreira A.L.A., Russell R.M., Rocha N.S., Ladeira M.S.P., Salvadori D.M.F., Nascimento M.C.M.O., Matsui M., Carvalho F.A., Tang G., Matsubara L.S., and Matsubara B.B. Effect of Lycopene on doxorubicin-induced cardiotoxicity: an echocardiographic, histological, and morphometrical assessment. Basic Clin. Pharmacol. Toxicol. 101 (2007) 16-24
68. Billingham M.E., Mason J.W., Bristow M.R., and Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 62 (1978) 865-872